New Frequently Asked Questions on COVID-19, vaccine distribution, and the impacts on the rare disease community. Click through for some common answers from our CSO and Scientific Advisory Board.

With your help, and the contributions of our co-chairs, Dr. Matthew Ellinwood and Patricia Espinal, our 2020 Annual Fund raised over $290,000!

Our December issue of printed Courage is out now, just in time for the holidays! It features 60 full-color pages of stories, family spotlights, program updates, science & research news, fundraising efforts, and more.

The annual award recognizes exceptional patient leadership advocacy in the field of lysosomal disease. Presentation will take place Monday, February 8, 2021 at the 17th Annual WORLDSymposium.

The recommended framework would qualify many individuals with MPS and ML to be among the first recipients of a COVID-19 vaccine when it becomes available.

Now recruiting patients born in: California, Michigan, New Jersey, New York This study is also recruiting any patients in any state who have privately banked cord blood and would provide a single-drop sample. Please contact Leslie Urdaneta directly if interested. This study is recruiting patients with MPS I (attenuated: Hurler-Scheie or Scheie Syndromes), MPS II, … Continued

Congratulations to all of this year’s recipients! We’re proud to share their stories and support their journeys.

The National MPS Society is pleased to announce the hiring of its inaugural Chief Scientific Officer (CSO), N. Matthew Ellinwood, D.V.M. Ph.D.

Current Study demonstrates potential to provide treatment to both prevent and reverse blindness for individuals with MPS I

We’re excited to share all of the groundbreaking research we are funding currently!